TRx Biosciences Announces Completion of Seed Round Fundraise
Cambridge, UK, 12th October 2021 – Funds secured from an esteemed group of private life science specialists allows creation of TRx’s wholly-owned product pipeline.
View ArticleNews
TRx signs Out-licensing Agreement with Monument Therapeutics
Cambridge, UK, 19th June 2021 – TRx announces its first technology licensing agreement in Neuroscience with digital biomarker specialist, Monument Therapeutics.
View ArticleTRx signs cannabinoid Research Agreement with Mandarapharma
Cambridge, UK, 27th April 2021 – TRx announces completion of its first cannabinoid research partnership in with strain informatics specialist, Mandarapharma.
View ArticleTRx Biosciences files Biodistribution Technology Platform IP
Cambridge, UK, 27th March 2021 – TRx’s proprietary technology platform represents a paradigm shift in the way that oral drug uptake is considered.
View ArticleTRx signs Research Agreement with Oxilio Limited for OXL001
Cambridge, UK, 13th January 2021 – TRx announces completion of its first research partnership in oncology with drug repurposing pioneer, Oxilio Limited.
View ArticleTRx Biosciences opens R&D facility at Babraham Campus, Cambridge
Cambridge, UK, 18th November 2020 – TRx commences development of its novel oral delivery platform, offering a step-change in drug biodistribution.
View Article